Researchers at Queen’s University and Kingston Health Sciences Centre (KHSC) will soon begin recruiting patients to study the efficacy of psychedelic-assisted therapy for the treatment of alcohol use disorder (AUD). The Phase 2b clinical trial, sponsored by Clairvoyant Therapeutics, will assess whether motivational enhancement therapy and the use of psilocybin...Read more
For the eleventh consecutive year, Kingston Health Sciences Centre (KHSC) and its research institute, the Kingston General Health Research Institute (KGHRI), has been named one of the Top 40 research hospitals in Canada by Research Infosource. As the research arm of KHSC, KGHRI is committed to cultivating patient-oriented research, building...Read more
For the tenth consecutive year, Kingston Health Sciences Centre (KHSC) has been named one of the Top 40 research hospitals in Canada by Re$earch Infosource. KHSC strives to be a leader in research projects that are aligned with regional population health needs. As the research arm of KHSC, Kingston General...Read more
Life in Ontario’s far north brings with it unique challenges. Depending on which community you call home, something as simple as running to the grocery store to pick up an ingredient when you’ve run out may not be easy. So, what happens then when you have a more urgent need;...Read more
Over the course of the pandemic, there has been one question about the COVID-19 virus that has continued to resurface. Why does the virus seem to more seriously affect certain patients more than others? Researchers at Kingston Health Sciences Centre (KHSC) are leading the Canadian efforts to find out; and...Read more
For many patients in southeastern Ontario, seeing a specialist at Kingston Health Sciences (KHSC) during the COVID-19 pandemic meant no longer having to make a trip to the hospital for an in-person clinic appointment. Instead, appointments often included the use of a laptop, iPad or smart phone, as medical teams...Read more
New licence agreement between Queen’s University and Taysha Gene Therapies could lead to development of treatments for rare diseases in children
FOR IMMEDIATE RELEASE
Monday, Sept. 28, 2020
KINGSTON, Ont. – Queen’s University announced that it has entered into a research collaboration and licensing agreement with Taysha Gene Therapies, Inc., for the development and commercialization of gene therapy for GM2 gangliosidoses.
The GM2 gangliosidoses are a group of degenerative/inflammatory diseases...Read more
It’s common for patients in need of critical care to experience some loss of muscle strength during their stay in an intensive care unit (ICU). Unfortunately, even if the patient was strong and mobile before their illness or injury, this can cause long-term issues with weakness and mobility.
“Most patients...Read more
One of the greatest unmet needs of patients with inflammatory bowel disease (IBD) is abdominal pain. Opioid drugs are the most effective treatment, but they have serious side effects.
However, new opioid drugs now in development offer longer-lasting pain relief with minimal side effects, and Dr. Stephen Vanner, a clinician-scientist...Read more
Dr. Chris Evans is no stranger to traumatic injuries. In fact, as the head of Kingston Health Sciences Centre’s (KHSC) trauma service, he sees the impact they can have on patients and families every day. But a new study is shining the light on the long-lasting effects of trauma that...Read more
- Page 1